irinotecan has been researched along with Renal Insufficiency in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, Y; Ando, Y; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Ariizumi, H; Fujita, KI; Hirasawa, Y; Ishida, H; Ishiguro, T; Kondo, Y; Kubota, Y; Kusuhara, H; Matsumoto, N; Ohkuma, R; Sasaki, Y; Tomoda, Y; Tsuboya, A; Tsunoda, T | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Armstrong, AE; Cohn, RA; Dargart, J; Gosiengfiao, Y; Matossian, D; Reichek, J; Walterhouse, DO | 1 |
| Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ | 1 |
| Seiter, K | 1 |
2 review(s) available for irinotecan and Renal Insufficiency
| Article | Year |
|---|---|
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
Toxicity of the topoisomerase I inhibitors.
Topics: Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan | 2005 |
1 trial(s) available for irinotecan and Renal Insufficiency
| Article | Year |
|---|---|
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Prospective Studies; Renal Dialysis; Renal Insufficiency | 2011 |
3 other study(ies) available for irinotecan and Renal Insufficiency
| Article | Year |
|---|---|
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Topics: Aged; Area Under Curve; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Tandem Mass Spectrometry; Topoisomerase I Inhibitors | 2021 |
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Neuroblastoma; Renal Dialysis; Renal Insufficiency; Temozolomide; Treatment Outcome | 2014 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies | 2017 |